Electrolytes and fluid management in hemodialysis and peritoneal dialysis

Nutrition in Clinical Practice

Volumn 20, Issue 2, 2005, Pages 192-201

  Nanovic, Lisa ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BICARBONATE; CALCITONIN; CALCIUM; CYCLIC GMP; GLUCONATE CALCIUM; INSULIN; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; POLYSTYRENESULFONATE SODIUM; POLYSTYRENESULFONIC ACID; POTASSIUM; SALBUTAMOL; SEVELAMER; SODIUM; ELECTROLYTE;

CALCINOSIS; CONFUSION; DIALYSATE; DRUG MECHANISM; DRUG TOLERANCE; ELECTROLYTE BALANCE; EXTRACELLULAR SPACE; FLUID BALANCE; HEART ARREST; HEART ARRHYTHMIA; HEMODIALYSIS; HOMEOSTASIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPONATREMIA; KIDNEY FAILURE; PERITONEAL DIALYSIS; POTASSIUM INTAKE; PRURITUS; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SODIUM RETENTION; ULTRAFILTRATION; VITAMIN SUPPLEMENTATION; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

ELECTROLYTES; HOMEOSTASIS; HUMANS; KIDNEY FAILURE; PERITONEAL DIALYSIS; RENAL DIALYSIS; TREATMENT OUTCOME; ULTRAFILTRATION; WATER-ELECTROLYTE BALANCE;

EID: 27744495041     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426505020002192     Document Type: Review

References (66)

1. Reddi A. Essentials of Renal Physiology. East Hanover, NJ: College Book Publishers; 1999.
2. Leypoldt JK, Cheung AK. Evaluating volume status in HD patients. Adv Ren Replace Ther. 1998;5:64-74.
3. rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
4. Saxenhofer H, Gnadinger MP, Weidmann P, et al. Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. Kidney Int. 1987;32:554-561.
5. Petersen J, Li CC, Bishop-Abney N, Seniw CM. Hemodynamic and atrial natriuretic peptide responses to fluid removal and reinfusion in HD patients. ASAIO Trans. 1988;34:509-511.
6. Lauster F, Heim JM, Drummer C, Fulle HJ, Gerzer R, Schiffl H. Plasma cGMP level as a marker of the hydration state in renal replacement therapy. Kidney Int. 1993;41(suppl):S57-S59.
7. Cheriex EC, Leunissen KM, Janssen JH, Mooy JM, van Hooff JP. Echography of the inferior vena cava is a simple and reliable tool for estimation of "dry weight" in haemodialysis patients. Nephrol Dial Transplant. 1989;4:563-568.
8. Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis. 1996;28:257-261.
9. Beto JA, Bansal VK. Medical nutrition therapy in chronic kidney failure: integrating clinical practice guidelines. J Am Diet Assoc. 2004;104:404-409.
10. rd ed. New York, NY: National Kidney Foundation; 2002.
11. th ed. New York, NY: McGraw-Hill; 2001:749-761.
12. Robertson GL. Abnormalities of thirst regulation. Kidney Int. 1984;25:460-469.
13. Walser M. Phenomenological analysis of renal regulation of sodium and potassium balance. Kidney Int. 1985;27:837-841.
14. th ed. Boston, MA: Little, Brown; 1997.
15. Hall JE, Jackson TE. The basic kidney-blood volume-pressure regulatory system: the pressure diuresis and natriuresis phenomena. In: Gyton AC, ed. Arterial Pressure and Hypertension. Philadelphia, PA: WB Saunders Co; 1998:87-99.
16. Flanigan MJ, LaGreca G, et al. Role of sodium in hemodialysis. Kidney Int. 2000;76(suppl 1):S72-S78.
17. Mitch WE, Wilcox CS. Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med. 1982;72:536-550.
18. Henrich WL, Woodard TD, Blachley JD, Gomez-Sanchez C, Pettinger W, Cronin RE. Role of osmolality in blood pressure stability after dialysis and ultrafiltration. Kidney Int. 1980;18:480-488.
19. Kimura G, Van Stone JC. A simulation study on transcellular fluid shifts induced by HD. Kidney Int. 1983;24:542-548.
20. Stiller S, Bonnie-Schorn E, Grassmann A, Uhlenbusch-Korwer I, Mann H. A critical review of sodium profiling for hemodialysis. Semin Dial. 2001;14:337-347.
21. Song JH, Lee SW, Suh CK, Kim JM. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling HD. Am J Kidney Dis. 2002;40:291-301.
22. Ramdeen G, Tzamaloukas AH, Malhotra D, Leger A, Murata GH. Estimates of interdialytic sodium and water intake based on the balance principle: differences between nondiabetic and diabetic subjects on hemodialysis. ASAIO J. 1998;44:812-817.
23. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9:1535-1543.
24. Hayes CP Jr, McLeod ME, Robinson RR. An extrarenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80:207-216.
25. Martin RS, Panese S, Virginillo M, et al. Increased secretion of potassium in the rectum of man with chronic renal failure. Am J Kidney Dis. 1986;8:105-110.
26. Kaji D, Thomas K. Sodium-potassium pump in chronic renal failure. Am J Physiol. 1987;252:F785-F793.
27. Moore R. Effects of insulin upon ion transport. Biochem Biophys Acta. 1983;737:1-49.
28. Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med. 1980;302:431-434.
29. DeFronzo RA, Bia M, Birkhead G. Epinephrine and potassium homeostasis. Kidney Int. 1981;20:83-91.
30. Adrogue HJ, Madias NE. Changes in plasma concentration during acute acid-base disturbances. Am J Med. 1981;71:456-467.
31. Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med. 1979;300:1087-1089.
32. Magner PO, Robinson L, Halperin RM, Zettle R, Halperin ML. The potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis. 1988;11:220-224.
33. Graber M. A model of the hyperkalemia produced by metabolic acidosis. Am J Kidney Dis. 1993;22:436-444.
34. Bastl CP, Hayslett JP. The cellular action of aldosterone in target epithelia. Kidney Int. 1992;42:250-264.
35. Ahmed J, Weisberg L. Hyperkalemia in dialysis patients. Semin Dial. 2001;14:348-356.
36. Latos DL, Strimel D, Drews MH, Allison TG. Acid-base and electrolyte changes following maximal and submaximal exercise in HD patients. Am J Kidney Dis. 1987;10:439-445.
37. Clark BA, Shannon C, Brown RS, Gervino EV. Extrarenal potassium homeostasis with maximal exercise in end-stage renal disease. J Am Soc Nephrol. 1996;7:1223-1227.
38. Hammer J, Oesterreicher C, Hammer K, Koch U, Traindl O, Kovarik J. Chronic GI symptoms in HD patients. Wien Klin Wochenschr. 1998;110:287-291.
39. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on HD. Ann Intern Med. 1989;110:426-429.
40. th ed. Philadelphia, PA: Lippencott-Raven; 1997.
41. Pohlmeier R, Vienken J. Phosphate removal and HD conditions. Kidney Int. 2001;59(suppl):S190-S194.
42. Musci I, Hercz G. Control of serum phosphate in patients with renal failure: new approaches. Nephrol Dial Transplant. 1998;13:2457-2460.
43. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and PTH levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770-779.
44. Amann K, Gross ML, London GM, Ritz E. Hyperphosphatemia: a silent killer of patients with renal failure? Nephrol Dial Transplant. 1999;14:2085-2087.
45. Block G. How should hyperphosphatemia be managed in dialysis patients? Semin Dial. 2002;15:315-317.
46. Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphatemia with hemodynamic disturbances in ESRD. Nephrol Dial Transplant. 1999;14:2178-2183.
47. Schiller LR, Santa Anna CA, Sheikh MS, Emmett M, Pordtran JS. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med. 1989;320:1110-1113.
48. Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in HD patients. J Am Soc Nephrol. 1992;3:96-102.
49. Finn WF, Joy MS, Hladi KG, Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004;62:193-201.
50. Block GA, Martin KJ, de Francisco AL, et al. Cina Calcet for secondary hyperparathyroidism in patients receiving HD. N Engl J Med. 2004;350:1516-1525.
51. Haas T, Hillon D, Dongradi G. Phosphate kinetics in dialysis patients. Nephrol Dial Transplant. 1991;6(suppl 2):S108-S113.
52. Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home hemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant. 1998;13:2853-2860.
53. Jacobson HR, Striker GE, Klahr S. Principles and Practice of Nephrology. Phildelphia, PA: Decker Inc; 1991.
54. Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol. 2004;24:422-426.
55. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic HD patients: a national study. Am J Kidney Dis. 1998;31:607-617.
56. Drueke TB. New pathogenic aspects of the secondary hyperparathyroidism of chronic renal failure. Kidney Blood Press Res. 1999;22:189-192.
57. Hruska KA, Teitelbaum SL. Mechanisms of renal disease: renal osteodystrophy. N Engl J Med. 1995;333:166-174.
58. Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E. Long term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis. 1996;28:704-712.
59. Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis. 1995;25:663-679.
60. Plum J, Schoenicke G, Kleophas W, et al. Comparison of body fluid distribution between chronic haemodialysis and PD patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant. 2001;16:2378-2385.
61. Enia G, Mallamaci F, Benedetto FA, et al. Long-term CAPD patients are volume expanded and display more sever left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant. 2001;16:1459-1464.
62. Konings CJ, Kooman JP, van der Sande FM, Leunissen KM. Fluid status in peritoneal dialysis: what's new? Perit Dial Int. 2003;23:284-290.
63. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12:1046-1051.
64. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of PD with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001;21:275-281.
65. Konings CJ, Kooman JP, Schonek M, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant. 2003;18:797-803.
66. Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in PD: International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20(suppl 4):S5-S21.